2018
Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination
Martin TCS, Vinetz JM. Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination. Malaria Journal 2018, 17: 89. PMID: 29466991, PMCID: PMC5822557, DOI: 10.1186/s12936-018-2243-3.Peer-Reviewed Original ResearchConceptsTransmission-blocking vaccinesPlasmodium vivax parasitaemiaLow transmission settingsControl of transmissionVivax parasitaemiaChloroquine resistanceAsymptomatic carriageMalaria eliminationNew therapiesPlasmodium vivaxImportant causeCarrier stateImmunological interactionsVaccineOnward infectionInfectionParasite transmissionEradication effortsMosquitoesMorbidityParasitaemiaTherapyMortalityDiagnosisVivax
2005
A global research agenda for leptospirosis.
Cachay E, Vinetz J. A global research agenda for leptospirosis. Journal Of Postgraduate Medicine 2005, 51: 174-8. PMID: 16333188, PMCID: PMC2270399.Peer-Reviewed Original ResearchConceptsImpact of leptospirosisVaccine-induced protective immunityEffective adjunct treatmentPublic health effortsAdjunct treatmentProtective immunityClinical leptospirosisHealth research fundingHealth effortsLeptospirosis pathogenesisAppropriate mobilizationSpirochetal diseasesLeptospirosisLeptospirosis transmissionCollaborative international effortDiseaseMammalian reservoirsTreatmentHealthVeterinary healthMorbidityRural areasPathogenesisGlobal research agendaMortality